Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced and Metastatic Breast Cancer
Interventions: DRUG: AZD2014|DRUG: Palbociclib|DRUG: Fulvestrant
Sponsor: AstraZeneca